- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
2014: Big HIT Market Expansion Ahead
The health IT market is poised for strong growth.
The health IT market is poised for strong growth.
Major factors driving this expansion are the rise in pressure to cut healthcare costs, increasing demand to integrate healthcare systems, high rate of return on investment, according to a Research and Markets report. And other prominent forces include financial support from the U.S. government, federal initiatives, the rise in aging population, growing demand for CPOE adoption in order to reduce medication errors, and the rise in incidences of chronic disorders.
“Healthcare information technology has emerged as a promising development to transform the paper-based healthcare system into a digitized one,” the report’s authors wrote. “HCIT also gives clinicians real-time access to patient data, and provides them with support to make the best possible decisions. It streamlines processes and reduces administrative overhead.
Read the full story here: http://bit.ly/JO6UEc
Source: Government HealthIT
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Optune Lua Device in NSCLC
October 16th 2024Optune Lua creates tumor-treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors or docetaxel to treat metastatic non–small cell lung cancer (NSCLC) that has not responded to platinum-based treatment.
Read More
